Investors & Partnerships
Pax Neuroscience is pursuing funding and strategic partner solutions to complete its clinical development and enter the market.
Investors
Pax’s IP and unique position offer investors an attractive opportunity for two investment rounds:
Seed
Funding purpose:
Final clinical trials, initial management infrastructure
Exploits R&D funding and progress to date
$5 million (May be organized into tranches)
Timing: Q2, 2025
Series A
Funding purpose:
Pharmaceutical products launch
Diagnostic product launch
$10 million
Timing: Q1, 2026
Strategic Partnerships
Pax is interested in partnerships that enable it to scale growth and operating capabilities with speed and certainty.
Potential partners include global, multinational, and national diagnostic, pharmaceutical and lab companies.